Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial
Kaplan, J. L., Rivas, V. N., Walker, A. L., Grubb, L., Farrell, A., Fitzgerald, S., … Stern, J. A. (2023, July 26). Journal of the American Veterinary Medical Association, Vol. 261, pp. 1628–1637.
MeSH headings : Animals; Cats; Cardiomyopathy, Hypertrophic / drug therapy; Cardiomyopathy, Hypertrophic / veterinary; Cardiomyopathy, Hypertrophic / pathology; Cat Diseases / drug therapy; Cat Diseases / pathology; Heart; Hypertrophy, Left Ventricular / drug therapy; Hypertrophy, Left Ventricular / veterinary; Hypertrophy, Left Ventricular / pathology; Myocardium / pathology; Sirolimus / administration & dosage; Delayed-Action Preparations / administration & dosage
topics (OpenAlex): Cardiovascular Conditions and Treatments; Cardiomyopathy and Myosin Studies; Trypanosoma species research and implications
TL;DR:
It is demonstrated that DR rapamycin was well tolerated and may prevent or delay progressive LV hypertrophy in cats with subclinical HCM and no demographic, echocardiographic, or clinicopathologic values were significantly different between study groups at baseline, confirming successful randomization.
(via Semantic Scholar)
Sources: Web Of Science, ORCID, NC State University Libraries
Added: February 6, 2024
What is Open Access?
Open access is the free, immediate, online availability of research
articles. Making your research open access allows researchers across
to globe read and interact with your work which may increase citations
to your work.
Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.